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Summary
Background Lung delivery of plasmid DNA encoding the CFTR gene complexed with a cationic liposome is a potential 
treatment option for patients with cystic ﬁ brosis. We aimed to assess the eﬃ  cacy of non-viral CFTR gene therapy in 
patients with cystic ﬁ brosis.
Methods We did this randomised, double-blind, placebo-controlled, phase 2b trial in two cystic ﬁ brosis centres with 
patients recruited from 18 sites in the UK. Patients (aged ≥12 years) with a forced expiratory volume in 1 s (FEV1) of 
50–90% predicted and any combination of CFTR mutations, were randomly assigned, via a computer-based 
randomisation system, to receive 5 mL of either nebulised pGM169/GL67A gene–liposome complex or 0·9% saline 
(placebo) every 28 days (plus or minus 5 days) for 1 year. Randomisation was stratiﬁ ed by % predicted FEV1 (<70 vs 
≥70%), age (<18 vs ≥18 years), inclusion in the mechanistic substudy, and dosing site (London or Edinburgh). Participants 
and investigators were masked to treatment allocation. The primary endpoint was the relative change in % predicted 
FEV1. The primary analysis was per protocol. This trial is registered with ClinicalTrials.gov, number NCT01621867.
Findings Between June 12, 2012, and June 24, 2013, we randomly assigned 140 patients to receive placebo (n=62) or 
pGM169/GL67A (n=78), of whom 116 (83%) patients comprised the per-protocol population. We noted a signiﬁ cant, 
albeit modest, treatment eﬀ ect in the pGM169/GL67A group versus placebo at 12 months’ follow-up (3·7%, 95% CI 
0·1–7·3; p=0·046). This outcome was associated with a stabilisation of lung function in the pGM169/GL67A group 
compared with a decline in the placebo group. We recorded no signiﬁ cant diﬀ erence in treatment-attributable adverse 
events between groups. 
Interpretation Monthly application of the pGM169/GL67A gene therapy formulation was associated with a signiﬁ cant, 
albeit modest, beneﬁ t in FEV1 compared with placebo at 1 year, indicating a stabilisation of lung function in the 
treatment group. Further improvements in eﬃ  cacy and consistency of response to the current formulation are needed 
before gene therapy is suitable for clinical care; however, our ﬁ ndings should also encourage the rapid introduction of 
more potent gene transfer vectors into early phase trials.
Funding Medical Research Council/National Institute for Health Research Eﬃ  cacy and Mechanism Evaluation 
Programme.
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Introduction
Cystic ﬁ brosis has been a target for gene therapy since the 
CFTR gene was cloned in 1989.1 Lung disease is the main 
cause of morbidity and mortality in individuals with cystic 
ﬁ brosis, with a median age at death of 29 years (95% CI 
27–31).2 Early expectations of a rapid breakthrough were 
based on supposed ease of access to the target respiratory 
epithelium via inhaled aerosols. These hopes were 
tempered by the subsequent realisation that the airways 
are well defended, in keeping with their predominant 
function as conducting passages, rather than absorptive 
surfaces. 
Various vectors for delivery of the CFTR gene into 
respiratory epithelial cells have been assessed. Viral 
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approaches, including adenoviruses, adeno-associated 
viruses, and retroviruses, have faltered because of 
ineﬃ  cient transduction from the luminal surface and 
immune responses restricting the eﬃ  cacy of repeated 
application.3 As such, research from the UK Cystic 
Fibrosis Gene Therapy Consortium has initially focused 
on non-viral vectors. Formulation and delivery of plasmid 
DNA–liposome complexes have been reﬁ ned in a large 
series of preclinical studies,4,5 and safety,6,7 molecular 
eﬃ  cacy, and practical doses have been assessed in several 
phase 1 and 2a studies in patients with cystic ﬁ brosis.1,3 
We did this study to assess the clinical eﬃ  cacy of the 
non-viral CFTR gene–liposome complex pGM169/
GL67A8 after repeated delivery to the airways. 
Methods
Study design and participants
We did this randomised, double-blind, placebo-
controlled, phase 2b trial in two cystic ﬁ brosis centres 
with patients recruited from 18 sites in the UK. Eligible 
participants had diagnosed cystic ﬁ brosis, were aged 
12 years or older, had a forced expiratory volume in 1 s 
(FEV1) of 50–90% predicted, and had any combination of 
CFTR mutations. 
The protocol was approved by the National Research 
Ethics Committee and the local Research Committees at 
the two dosing sites and the 16 other referral centres. 
Each patient, or a parent, provided written informed 
consent, and children provided assent. 
Randomisation and masking
We randomly assigned patients (1:1), via a computer-based 
randomisation system, to receive nebulised pGM169/
GL67A or 0·9% saline (placebo). Randomisation was 
stratiﬁ ed by % predicted FEV1 (<70 vs ≥70%), age (<18 vs 
≥18 years), inclusion in the mechanistic substudy, and 
dosing site (London or Edinburgh). Participants in the 
mechanistic substudy were randomly assigned (2:1) to 
receive nebulised pGM169/GL67A or placebo, and could 
participate as part of either a nasal or bronchoscopy group, 
or both. Participants and investigators were masked to 
treatment allocation, with the randomisation code known 
only by pharmacy staﬀ  at the two dosing sites. 
Procedures 
Patients received 5 mL of either 0·9% saline or pGM169/
GL67A complex nebulised through a Trudell AeroEclipse 
II device (Trudell Medical International, London, ON, 
Canada) at 28 day intervals (plus or minus 5 days) for 
12 months. Each 5 mL dose of pGM169/GL67A contained 
13·3 mg of plasmid DNA and 75 mg of the GL67A lipid 
mixture. Routine treatments were continued throughout 
the study, except for DNase, which was withheld for 24 h 
before and after dosing. In addition to the nebulised 
dose, patients in the nasal group of the mechanistic 
substudy received 2 mL of placebo or pGM169/GL67A 
divided between nasal cavities via a nasal spray device at 
the time of each lung dose. Patients in the bronchoscopy 
group followed the standard protocol, but also underwent 
a bronchoscopy under general anaesthesia before the 
ﬁ rst dose and 28 days (plus or minus 5 days) after the 
ﬁ nal dose.
Outcomes
The primary eﬃ  cacy endpoint was the relative change in 
% predicted FEV1, calculated from the mean of two 
baseline values (at screening and before dosing on day of 
the ﬁ rst dose) to the mean of two values (2 and 4 weeks 
after last dose) at study completion. Secondary outcomes 
included additional measurements of lung function, CT 
scans, and Cystic Fibrosis Questionnaire-Revised (CFQ-R) 
scores.9 Exploratory endpoints included exercise testing, 
activity monitoring, and sputum inﬂ ammatory markers. 
Mechanistic endpoints were nasal or bronchial vector-
speciﬁ c DNA, mRNA, and electrophysiological assessment 
of CFTR function. We did extensive safety assessments.
Statistical analysis
The statistical analyses were prespeciﬁ ed in a statistical 
analysis plan. With use of pilot data, we estimated the 
standard deviation of the relative change in % predicted 
FEV1 in the target cystic ﬁ brosis population to be 10% 
over 12 months. A total sample size of 120 assessable 
patients would provide 90% power to detect a 6% 
diﬀ erence between groups in the mean change from 
baseline at a two-sided 5% signiﬁ cance level. This power 
calculation was conservative because covariate 
Research in context
Evidence before this study
We searched PubMed between June 1, 1992, and March 1, 2015, 
for studies published that included the terms ”non-viral, gene 
therapy, cystic ﬁ brosis” or ”liposome, gene therapy, cystic ﬁ brosis”.
Added value of this study
We report the ﬁ rst trial of non-viral CFTR gene therapy for 
patients with cystic ﬁ brosis that is powered to detect clinically 
relevant pulmonary changes. Our study has progressed this ﬁ eld 
of research from phase 1 and 2a studies showing changes in 
molecular surrogates of CFTR function, to a phase 2b setting 
assessing changes in lung function in patients with a broad 
range of CFTR mutations. Additionally, our study shows that 
monthly repeated application of non-viral gene therapy can be 
safely administered to the lungs over a 1 year period.
Implications of all the evidence
By providing the ﬁ rst proof of concept that non-viral gene 
therapy can beneﬁ cially aﬀ ect lung function, follow-up studies 
can assess optimum dose, dosing interval, and patient 
stratiﬁ cation at trial entry. Our ﬁ ndings are likely to catalyse earlier 
translation of more eﬃ  cient vectors into ﬁ rst-in-man trials.
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See Online for appendix adjust ment can be expected to increase statistical power. 
We did analyses in the per-protocol population (primary 
analysis), predeﬁ ned as participants who received at least 
nine doses of pGM169/GL67A or placebo, and in the 
intention-to-treat population, who received at least one 
dose of pGM169/GL67A or placebo. 
We compared outcomes between groups with an 
ANCOVA model, with inclusion of the relevant baseline 
value, treatment allocation, and stratiﬁ cation factors 
(baseline predicted FEV1, age, dosing site, inclusion in 
substudy). Results are reported as adjusted mean 
diﬀ erences with corresponding 95% CIs. We assessed 
subgroup eﬀ ects by including the relevant interaction 
term in the ANCOVA model. To allow results from 
diﬀ erent endpoints to be plotted on a common scale, the 
estimated treatment eﬀ ects were standardised and 
presented as multiples of the underlying SD. No adjust-
ment was made to the p values to allow for multiplicity 
because the secondary endpoints were supportive and 
the corresponding p values were interpreted con ser-
vatively. We assessed bronchial and nasal biomarkers 
with a Mann–Whitney U test. A two-sided p value less 
than 0·05 was considered statistically signiﬁ cant.
The trial was overseen by an independent Data 
Monitoring and Ethics Committee and a Trial Steering 
Committee. This trial is registered with ClinicalTrials.
gov, number NCT01621867.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Figure 1 shows the trial proﬁ le. Between June 12, 2012, 
and June 24, 2013, we randomly assigned 140 patients to 
receive placebo (n=62) or pGM169/GL67A (n=78), of 
whom 136 (97%) patients comprised the intention-to-treat 
population and 116 (83%) patients comprised the per-
protocol population (ﬁ gure 1). Reasons for discontinuation 
in the intention-to-treat population were similar between 
groups (appendix). Baseline characteristics were similar 
between the two groups (table 1). Unless indicated 
otherwise, all subsequent details relate to the per-protocol 
population. 
114 (98%) patients had paired pre-treatment and post-
treatment measurements of % predicted FEV1. Of the 
two patients (both in the placebo group) who did not 
have paired measurements, one patient could not do the 
test because of a surgery-related pneumothorax and one 
withdrew because of time commitments and was 
unavailable for follow-up measurements. We recorded a 
signiﬁ cant ANCOVA-adjusted treatment eﬀ ect in the 
pGM169/GL67A group versus placebo at 12 months’ 
follow-up (3·7%, 95% CI 0·1–7·3; p=0·046; ﬁ gure 2) 
The relative changes within each of the individual 
groups were –4·0% (95% CI –6·6 to –1·4) in the placebo 
group and –0·4% (–2·8 to 2·1) in the pGM169/GL67A 
group (ﬁ gure 2). Post-hoc analysis showed that 21 (18%) 
patients (n=6 in the placebo group and n=15 in the 
pGM169/GL67A group) had an improvement in % 
predicted FEV1 of 5% or more of their individual 
baseline values. For comparison, the treatment eﬀ ect in 
patients in the inten tion-to-treat population who had 
spirometry measure ments both before dosing and 
within the protocol-deﬁ ned window after their ﬁ nal 
dose (n=56 in the placebo group and n=65 in the 
pGM169/GL67A group) was 3·6% (95% CI 0·2–7·0; 
191 patients invited for screening
40 excluded
13 had FEV1 <50%
19 had FEV1 >90%
4 were clinically unstable
3 had clinically signiﬁcant liver disease
1 absence of evidence of cystic ﬁbrosis 
diagnosis
151 eligible for inclusion
11 discontinued
9 withdrew consent
2 developed exclusion criteria
140 randomised
62 assigned to receive placebo
51 in main cohort
4 in bronchoscopy subgroup only
4 in nasal subgroup only
3 in both subgroups
78 assigned to receive pGM169/GL67A
52 in main cohort
9 in bronchoscopy subgroup only
10 in nasal subgroup only
7 in both subgroups
2 discontinued
1 clinically unstable
1 withdrew consent
2 discontinued
2 withdrew consent
60 received placebo
6 discontinued
1 commenced ivacaftor
1 developed exclusion 
criteria
4 withdrew consent
54 received at least nine doses
76 received pGM169/GL67A
14 discontinued
2 commenced ivacaftor
3 developed exclusion 
criteria
1 missed three or more 
doses
8 withdrew consent
62 received at least nine doses
Intention 
to treat
Per protocol
Figure 1: Trial proﬁ le
Numbers of patients in the intention-to-treat population are unequal because of the 2:1 allocation in the 
mechanistic substudy. FEV1=forced expiratory volume in 1 s.
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p=0·039), with the 20 patients included in the intention-
to-treat, but not per-protocol, analysis, receiving a mean 
of 3·7 doses (SD 1·9). 
Figure 3 summarises changes in a range of secondary 
outcomes. The treatment eﬀ ect was signiﬁ cant for FVC 
(p=0·031; appendix) and CT gas trapping (p=0·048), but 
not for other measures of lung function, imaging, and 
quality of life (ﬁ gure 3). We assessed whether a responder 
subgroup could be identiﬁ ed; the appendix summarises 
the prespeciﬁ ed subgroups. We noted no signiﬁ cant 
diﬀ erences in the primary outcome treatment eﬀ ect with 
respect to sex, age, CFTR mutation (phe508del homo-
zygous vs other), Pseudomonas colonisation, predominant 
smaller or larger airway disease on CT at presentation, 
concurrent drugs, or treatment-associated adverse events 
(appendix). Although some subgroups had larger 
treatment eﬀ ects than others, these results were typically 
due to a greater decline in FEV1 in the placebo group, 
rather than to any diﬀ erence of eﬀ ect in the pGM169/
GL67A group (appendix). Stratiﬁ cation by baseline 
% predicted FEV1 suggested a diﬀ erence, albeit non-
signiﬁ cant, in treatment eﬀ ect between patients with 
more severe disease (FEV1 49·6–69·2% predicted), who 
had a treatment eﬀ ect of 6·4% (95% CI 0·8–12·1), and 
those with less severe disease (69·6–89·9% predicted), 
who had a treatment eﬀ ect of 0·2% (–4·6 to 4·9; 
pinteraction=0·065; appendix). In patients with more severe 
disease, post-trial and pre-trial changes in both the 
placebo group (–4·9%) and the pGM169/GL67A group 
(1·5%) contributed to the treatment eﬀ ect. Secondary 
outcomes showed a similar trend favouring the more 
severe category (appendix).
Patients in both treatment groups received a median of 
three (IQR one to ﬁ ve) courses of oral or intravenous 
antibiotics during the trial. Speciﬁ cally, we assessed co-
administered antibiotics during the critical analysis 
period from dose 11 to the end of the trial. Numbers of 
patients receiving any additional antibiotics were 
26 (48%) in the placebo group and 30 (51%) in the 
Placebo group 
(n=54)
pGM169/GL67A group 
(n=62)
Age (years) 26·0 (13·0) 23·6 (10·8)
<18 years old 17 (31%) 23 (37%)
≥18 years old 37 (69%) 39 (63%)
Sex 
Female 25 (46%) 31 (50%)
Male 29 (54%) 31 (50%)
Centre distribution number
Edinburgh 24 (44%) 22 (35%)
London 30 (56%) 40 (65%)
Height (cm) 165·0 (10·6) 163·6 (10·9)
Weight (kg) 61·6 (15·6) 61·0 (15·7)
FEV1 (% predicted) 69·0 (9·9) 69·9 (11·1)
Body-mass index (kg/m²) 22·4 (4·4) 22·4 (4·5)
Mutation class
Phe508del/Phe508del 26 (48%) 31 (50%)
Phe508del/class 1–6 22 (41%) 23 (37%)
Not Phe508del/class 1 1 (2%) 3 (5%)
Heterozygous/homozygous 
class 3–6
2 (4%) 2 (3%)
Phe508del/unknown class 3 (6%) 3 (5%)
Data are mean (SD) or n (%), unless otherwise indicated.
Table 1: Baseline and demographic characteristics  
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C
Figure 2: Timecourse of the primary outcome response to either placebo or 
pGM169/GL67A (A) and the individual patient responses in the pGM169/
GL67A (B) and placebo (C) groups 
Error bars in panel A show the standard error of the mean. Primary outcome 
measurements were taken at each treatment visit before administration of 
study drugs. Pre and post values indicate the mean of two measurements at the 
respective timepoints. Positive values in panels B and C show an improvement. 
FEV1=forced expiratory volume in 1 s.
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pGM169/GL67A group (χ² p=0·774). Thus, the observed 
FEV1 treatment eﬀ ect was considered to be independent 
of concurrent antibiotic courses. 
No clinically relevant pattern of changes could be 
distinguished in the exploratory outcomes of activity and 
exercise monitoring and serum and sputum inﬂ am matory 
markers (appendix). In the bronchoscopy group of the 
substudy, vector-speciﬁ c DNA increased in 12 (86%) of 
14 patients in the pGM169/GL67A group and was below 
the limit of quantiﬁ cation in all (n=7) placebo samples 
(p=0·001; ﬁ gure 4A); vector-speciﬁ c mRNA was below the 
level of sensitivity in both groups (appendix). Changes in 
basal post-trial and pre-trial potential diﬀ erence values did 
not diﬀ er signiﬁ cantly in either group (appendix). Figure 4B 
shows bronchial chloride responses using the mean of all 
interpretable tracings for each patient; a negative value 
indicates a change in the non-cystic ﬁ brosis direction. 
Patients in the placebo group (n=7) had a median change 
(post-trial minus pre-trial) of 3·1 mV (range 9·3 to –1·2) 
and those in the pGM169/GL67A group (n=10) had a 
change of –1·3 mV (4·0 to –5·8; p=0·032; ﬁ gure 4B). Five 
(50%) of ten patients in the pGM169/GL67A group had 
values that were more negative than the largest response 
in the placebo group (ﬁ gure 4). In the same analysis with 
only the most negative value recorded for each patient at 
any timepoint, patients in the placebo group had a median 
post-trial minus pre-trial change of 2·6 mV (range 9·3 to 
–1·2) and those in the pGM169/GL67A group had a change 
of –2·8 mV (4·0 to –16·8 mV; p=0·088; ﬁ gure 4C). Six 
(60%) patients in the pGM169/GL67A group had values 
that were more negative than the largest response in the 
placebo group (ﬁ gure 4). The appendix shows absolute 
bronchial potential diﬀ erence values. 
In patients in the nasal group of the substudy, vector-
speciﬁ c DNA increased in all the 17 patients given pGM169/
GL67A. Despite apparent pGM169 con tami nation in some 
samples, the change in pGM169 con cen trations diﬀ ered 
signiﬁ cantly between the groups (appendix); no 
–1·0 –0·5 0 0·5 1·0
54/60
54/60
51/59
54/61
54/61
54/61
54/61
54/61
54/61
54/61
54/60
54/61
51/61
52/61
27/22
54/60
54/61
48/55
51/61
Primary endpoint
FEV1
Lung function
FVC
MEF25–75
Lung clearance index
CT
Bronchiectasis extent
Bronchiectasis severity
Wall thickness
Large airway mucus plugs
Small airway mucus plugs
Gas trapping
Health-related quality of life*
Physical functioning
Respiratory symptoms
Safety
C-reactive protein
Erythrocyte sedimentation rate
White blood cells
KCOc
TLCOc
Alveolar volume
Sputum 24 h weight
 69·48 (10·50)
 83·94 (11·54)
 1·63 (0·71)
 10·78 (2·45)
 1·92 (0·74)
 1·80 (0·74)
 1·84 (0·60)
 0·81 (0·38)
 0·85 (0·33)
 4·65 (12·85)
 82·87 (18·9)
 78·78 (14·25)
 7·32 (9·67)
 12·88 (11·01)
 8·58 (2·79)
 1·91 (0·22)
 8·02 (2·10)
 4·23 (1·12)
 10·96 (11·73)
Placebo/pGM169/GL67A (N) Pre-treatment Absolute 
treatment eﬀect
Standardised 
treatment eﬀect
Adjusted 
p value
0·046
0·031
0·362
0·187
0·564
0·116
0·146
0·369
0·061
0·048
0·584
0·425
0·057
0·272
0·176
0·257
0·302
0·331
0·239
Favours placebo Favours pGM169/GL67A
Standardised treatment eﬀect
3·66 (0·07 to 7·25)
3·03 (0·29 to 5·78)
0·07 (–0·08 to 0·22)
–0·28 (–0·71 to 0·14)
–0·03 (–0·13 to 0·07)
–0·08 (–0·17 to 0·02)
–0·09 (–0·21 to 0·03)
–0·03 (–0·1 to 0·04)
–0·07 (–0·15 to 0·00)
–3·49 (–6·96 to –0·03)
1·82 (–4·75 to 8·39)
2·08 (–3·06 to 7·22)
–4·82 (–9·8 to 0·15)
–1·86 (–5·21 to 1·48)
–0·52 (–1·28 to 0·24)
0·03 (–0·02 to 0·08)
0·18 (–0·16 to 0·51)
0·07 (–0·07 to 0·21)
–2·96 (–7·97 to 2·05)
0·39 (0·01 to 0·77)
0·42 (0·04 to 0·80)
0·18 (–0·21 to 0·56)
0·26 (–0·13 to 0·66)
0·11 (–0·27 to 0·50)
0·31 (–0·08 to 0·69)
0·28 (–0·1 to 0·66)
0·18 (–0·21 to 0·56)
0·37 (–0·02 to 0·75)
0·39 (0·00 to 0·77)
0·11 (–0·28 to 0·50)
0·16 (–0·23 to 0·54)
0·39 (–0·01 to 0·80)
0·21 (–0·17 to 0·59)
0·26 (–0·12 to 0·64)
0·23 (–0·17 to 0·63)
0·21 (–0·19 to 0·60)
0·19 (–0·20 to 0·57)
0·36 (–0·25 to 0·98)
Figure 3: Forest plot showing secondary outcome responses to placebo or pGM169/GL67A
Data are mean (SD) or mean (95% CI), unless otherwise indicated. The size of the circles is proportional to the number of patients represented and the error bars show 
95% CIs. Values shown for FEV1 are the relative change in the % predicted FEV1. To allow results from diﬀ erent endpoints to be plotted on a common scale, the 
estimated treatment eﬀ ects were standardised to be presented as multiples of the underlying SD (standardised treatment eﬀ ect). FEV1=forced expiratory volume in 1 s. 
MEF25–75=mid-expiratory ﬂ ow between 25% and 75% of FVC. KCOc=diﬀ usion capacity of the alveolar capillary membrane, corrected for haemoglobin concentrations. 
TLCOc=transfer factor of the lung for carbon monoxide, corrected for haemoglobin concentrations. *Refers to scores from the Cystic Fibrosis Questionnaire-Revised.
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vector-speciﬁ c mRNA was quantiﬁ able in either group. We 
noted no signiﬁ cant changes in the baseline, zero chloride, 
or isoprenaline responses (appendix). Four (29%) of 
14 pGM169/GL67A patients had mean post-trial minus pre-
trial treatment responses (ranging from –3·4 mV to 
–7·0 mV) that were more negative than the largest response 
in the placebo group (n=6; appendix). The appendix shows 
absolute nasal potential diﬀ erence values. 
All patients had adverse events, with no signiﬁ cant 
diﬀ erence between groups for either total events or 
within the nine predeﬁ ned adverse event categories 
(table 2). One patient in the placebo group and one 
patient in the pGM169/GL67A group discontinued study 
treatment because of adverse events (fatigue and 
increased respiratory symptoms and ﬂ u-like symptoms, 
respectively). We recorded six serious adverse events, all 
in the pGM169/GL67A group (appendix). Neither the 
Data Monitoring and Ethics Committee nor the Trial 
Steering Committee regarded any serious adverse event 
as related to study drug; however, one event was 
considered to be possibly related to a trial procedure 
(bronchoscopy). We noted no clinically relevant changes 
in haematology, biochemistry, conversion of anti-CFTR 
T cells, anti-DNA antibodies, histology, or lipid staining 
(appendix) and no patients died during the study.
Discussion
We report the ﬁ rst trial of non-viral based gene therapy 
for cystic ﬁ brosis, powered to detect clinically relevant 
pulmonary changes. After monthly dosing for 1 year, we 
recorded evidence of a beneﬁ cial eﬀ ect of gene therapy 
versus placebo on FEV1. No eﬀ ect of sex, age, or whether 
patients were homozygous for the most common 
F508del CFTR mutation could be detected. No clinically 
important adverse events attributable to treatment with 
pGM169/GL67A were reported. 
Although these ﬁ ndings are encouraging, they should be 
put into perspective. We noted a stabilisation of FEV1 in the 
pGM169/GL67A group rather than an improve ment. This 
stabilisation took place over a 1 year period and further 
work will be needed to see if this eﬀ ect is maintained. The 
reduction in FEV1 in the placebo group was within the 
range reported in some other prospective trials10–12 and is 
consistent with a median survival of 29 years, but is greater 
than would be expected from registry data.2 Three factors 
are likely to have inﬂ uenced this diﬀ erence. First, the 
requirement for clinical stability at trial entry meant that 
patients might have been at their optimum respiratory 
health at this stage. Second, the enthusiasm of patients to 
enter the trial, accompanied by a focus on self-care, might 
have resulted in short-term improve ments in lung function 
during the recruitment period. Both factors are likely to 
lead to a subsequent decline in lung function as patients 
regress to their mean values. Third, we included all 
available data, whether from stable patients or those with 
exacerbations, by contrast with registry data, which focuses 
on measurements obtained at annual review. Stabilisation 
of lung disease in itself is a worthwhile aim and we would 
caution against the bar being set too high for novel 
therapeutics in cystic ﬁ brosis populations with an 
unselected range of mutations. The large response to 
ivacaftor in patients with class III mutations takes place in 
the context of correctly localised CFTR protein. By contrast, 
much smaller improvements in lung function were shown 
in the ivacaftor–lumacaftor trial for the most common 
mutation (phe508del) in which the CFTR protein is 
misfolded and mislocalised.13 
The response in our study was heterogeneous, with 
apparent responders and non-responders. The data 
suggest that an approximate doubling of treatment eﬀ ect 
was achieved in patients with more severe disease stratiﬁ ed 
by baseline FEV1, supported by trends in other clinically 
relevant secondary measures. A larger trial with a stratiﬁ ed 
trial entry design, powered to assess subgroups, and that 
addresses the mechanisms of response heterogeneity, will 
Placebo group (n=54) pGM169/GL67A group (n=62)
Lower airway respiratory symptoms 7·9 9·0
Gastrointestinal symptoms 2·1 1·8
Fever or ﬂ u-like symptoms 1·1 1·4
Headache 1·2 1·1
Upper airway symptoms 2·3 3·4
Elevated liver function tests 0·3 0·4
Haematuria 0·2 0·2
Isolated raised inﬂ ammatory markers 0·8 0·7
Other 3·2 3·3
Total 19·1 21·2
Data are mean number of times the respective symptom was experienced by each patient during the trial. Values were 
calculated by dividing the total number of the relevant adverse event by the total number of relevant patients in that group.
Table 2: Adverse events
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Figure 4: Assessment of DNA from bronchial brushings in the placebo (n=7) and pGM169/GL67A (n=14) 
subgroups (A) and the response of the bronchial epithelium to perfusion with a zero chloride solution 
containing isoprenaline 10 μM (B, C) 
Horizontal bars show median values. Each circle in panel A represents an individual patient. Each symbol in panels 
B and C shows the change in response from trial start to ﬁ nish for the relevant treatment in an individual patient. 
Of the 16 participants in the bronchoscopy subgroup, 15 individuals had post-dose bronchoscopies, of whom 
14 individuals generated samples for DNA and mRNA molecular analysis. The plotted value in panel B is the mean 
of all interpretable recordings (range 1–3), and in panel C is the most negative value obtained from all interpretable 
recordings, at each timepoint for that patient. A more negative value is in the non-cystic ﬁ brosis direction. 
LOQ=limit of quantiﬁ cation, PBNQ=positive but not quantiﬁ able. 
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be important to verify or refute these data. This diﬀ erential 
response could relate to the dose deposited in the airways; 
in patients with lower baseline FEV1 the relatively more 
obstructed smaller airways result in a larger proportion of 
the 5 mL dose being deposited in the larger airways. In 
pre-trial studies we assessed airway deposition in patients 
with cystic ﬁ brosis with varying FEV1 severity with 
technetium-99m labelled human serum albumin of 
similar droplet size (3–4 μm, using a diﬀ erent nebuliser 
system) to the pGM169/GL67A formulation. Bronchial 
airway (generations 2–8) fractional deposition was 2·9% of 
delivered dose (standard error of the mean [SEM] 0·2; 
n=33) in patients with 70–90% predicted FEV1 and roughly 
twice as great (6·0%, SEM 1·0; n=23) in those with 50–
70% predicted FEV1. An additional contributory factor to 
this enhanced eﬃ  cacy might be the increased mitotic rate 
of more severely aﬀ ected tissues,14 which decreases the 
proportion of time that the nuclear membrane is intact, 
the membrane acting as a barrier to plasmid DNA entry to 
the nucleus. 
We cannot rule out that the changes recorded in the 
present study are the result of a non-speciﬁ c response to 
the pGM169/GL67A formulation. The placebo was 0·9% 
saline rather than a scrambled or CFTR-deleted plasmid–
liposome complex. We selected 0·9% saline partly on the 
basis of pragmatic ﬁ nancial considerations, but mainly for 
ethical considerations, not wishing to expose patients with 
cystic ﬁ brosis to ﬁ rst-in-man repeated pulmonary dosing of 
an untested product that might direct the expression of an 
immunologically active peptide or novel non-coding RNA 
molecule with deleterious biological functions. 
Furthermore, we wanted to compare pro gression on 
therapy with the natural history of the disease. In terms of 
alternative explanations for the eﬀ ects we noted, we know 
of no evidence that monthly nebulisation of 0·9% saline is 
deleterious to lung function, nor that liposome alone 
produces physiological improvements in either patients 
without,15 or those with16 cystic ﬁ brosis. Delivery of non-
CFTR encoding plasmid DNAs to the human airways has 
not been associated with a gain in CFTR chloride-channel 
function, nor improvement in any cystic ﬁ brosis-related 
assay,17,18 and plasmid DNA is generally associated with pro-
inﬂ am matory, rather than non-speciﬁ c, beneﬁ cial eﬀ ects.19 
We did not identify any pathophysiological changes in the 
airways, such as inﬂ ammation or remodelling, nor any 
changes in bacterial species that might otherwise explain 
the outcomes. Nevertheless, we cannot exclude that DNA–
liposome complexes augment host defences, stimulate 
mucus clearance, or enhance bacterial killing to an extent 
undetectable on semi-quantitative routine culture. 
Results showing more robust changes in molecular 
CFTR surrogates would have been reassuring. Despite 
extensive optimisation of quantitative realtime-PCR assays, 
the pGM169-derived mRNA assay has poor sensitivity and 
is adversely aﬀ ected by the inclusion of high levels of total 
RNA or modest concentrations of pGM169 plasmid DNA. 
In ovine studies we have shown that a 20 mL nebulised 
dose of pGM169/GL67A, four times that used in the 
present trial, is the lower threshold for reproducible 
detection of mRNA with this assay in airway tissue samples 
(unpublished).6 Thus, our inability to detect pGM169-
derived mRNA after delivery of 5 mL of pGM169/GL67A to 
the human airways, although disappointing, was not 
surprising. In human tissues, we have noted the low 
sensitivity of assays assessing vector-speciﬁ c mRNA from 
human samples in vivo,16,20,21 and have noted the greater 
sensitivity of detection of electrophysiological changes, 
consistent with ﬁ ndings in this study.17,18,22 
The ratio of area sampled to area dosed is small. Although 
we recorded signiﬁ cant chloride secretory changes in the 
bronchial, but not the nasal, epithelium, we caution against 
placing undue weight on either observation. The size of the 
groups in the mechanistic substudy was limited by both the 
practicality of the procedures and the acceptability to 
patients of the additional invasive tests, leading to low 
statistical power for these measures. We would instead 
conclude that modest variable changes can be shown with 
currently available assays that remain insuﬃ  ciently 
sensitive to detect changes in low levels of CFTR function 
when assessed in vivo in humans; further optimisation in 
these or other assays is needed. 
Although we are encouraged by the ﬁ rst demonstration 
of a signiﬁ cant beneﬁ cial eﬀ ect in lung function 
compared with placebo associated with gene therapy in 
patients with cystic ﬁ brosis, the mean diﬀ erence was 
modest, only recorded in some individuals, and at the 
lower end of the range of results seen in clinical trials 
which result in changes in patient-related care.23,24 We did 
not formally assess infective exacerbations in view of the 
fairly small patient numbers in our study, but use of 
antibiotic courses as a surrogate identiﬁ ed no obvious 
treatment advantage. The treatment eﬀ ect is consistent 
with a clinically meaningful beneﬁ t from the perspective 
of the European Medicine Agency;25 however, further 
improvements in eﬃ  cacy and consistency of response to 
the current formulation, or its combination with CFTR 
potentiators, are needed before gene therapy is suitable 
for clinical practice. Furthermore, our ﬁ ndings should 
encourage the rapid introduction of more potent gene 
transfer vectors into early phase trials, now that much of 
the groundwork has been established. 
The data reported here provide the ﬁ rst proof of 
concept that repeated administration of non-viral CFTR 
gene therapy can safely change clinically relevant 
parameters, providing another step along the path of 
translational cystic ﬁ brosis gene therapy.
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